Clinical Trial Update: PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas [Phase 1]

View source ↗

Summary

A Phase I trial evaluated adding a Farnesyl Transferase Inhibitor to temozolomide in patients with Grade 3-4 malignant gliomas, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Farnesyl transferase inhibitor
• Temodar (Temozolomide)

Snippet

Sponsor: Duke University | Conditions: Gliosarcoma, Glioblastoma | Phase 1 | Status: COMPLETED